Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia

References

• Stahl JP, Mailles A, Dacheux L, Morand P. Epidemiology of viral encephalitis in 2011. Med Mal Infect. 2011;41(9):453–8. doi:10.1016/j.medmal.2011.05.015 .
   PubMed Web of Science ®Google Scholar
• Mayxay M, Douangdala P, Vilayhong C, Phommasone K, Chansamouth V, Vongsouvath M, Rattanavong S, Chang K, Sengvilaipaseuth O, Chanthongthip A, et al. Outcome of Japanese Encephalitis Virus (JEV) infection in pediatric and adult patients at Mahosot Hospital, Vientiane, Lao PDR. Am J Trop Med Hyg. 2021 Feb;104(2):567–75. doi:10.4269/ajtmh.20-0581 .
   Web of Science ®Google Scholar
• Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. J Neurol Neurosurg Psychiatry. 2000;68(4):405–15. doi:10.1136/jnnp.68.4.405 .
   PubMed Web of Science ®Google Scholar
• Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination:: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15 October 1998. Vaccine. 2000;18:1–25. doi:10.1016/S0264-410X(00)00037-2 .
   PubMed Web of Science ®Google Scholar
• Muangchana C, Henprasertthae N, Nurach K, Theppang K, Yoocharoen P, Varinsathien P, Techathawat S, Sanohsieng S, Anantapreecha S. Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: a case–control study. Vaccine. 2012;30(2):361–67. doi:10.1016/j.vaccine.2011.10.083 .
   PubMed Web of Science ®Google Scholar
• Yen NT, Duffy MR, Hong NM, Hien NT, Fischer M, Hills SL. Surveillance for Japanese encephalitis in Vietnam, 1998–2007. Am J Trop Med Hyg. 2010;83(4):816–19. doi:10.4269/ajtmh.2010.10-0262 .
   PubMed Web of Science ®Google Scholar
• Hanna JN, Ritchie SA, Phillips DA, Shield J, Bailey MC, Mackenzie JS, Poidinger M, McCall BJ, Mills PJ. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust. 1996;165(5):256–60. doi:10.5694/j.1326-5377.1996.tb124960.x .
   PubMed Web of Science ®Google Scholar
• Hanna JN, Ritchie SA, Hills SL, Hurk AF, Phillips DA, Pyke AT, Lee JM, Johansen CA, Mackenzie JS. Japanese encephalitis in north Queensland, Australia, 1998. Med J Aust. 1999;170(11):533–36. doi:10.5694/j.1326-5377.1999.tb127878.x .
   PubMed Web of Science ®Google Scholar
• The Age. Victorian man dies after contracting Japanese encephalitis in Phuket, Thailand. 2017 [accessed 2021 Nov]. https://www.theage.com.au/national/victoria/victorian-man-dies-after-contracting-rare-and-potentially-fatal-japanese-encephalitis-virus-in-thailand-20170622-gwvztd.html .
   Google Scholar
• Christian N. Australians warned about travelling to Bali amid spike in Japanese encephalitis cases. 2018 [accessed 2021 Nov]. https://www.news.com.au/travel/travel-updates/warnings/australians-warned-about-travelling-to-bali-amid-spike-in-japanese-encephalitis-cases/news-story/e255ca32f524bcbdae9d1ee1f7e3a429 .
   Google Scholar
• Pyke AT, Choong K, Moore F, Schlebusch S, Taylor C, Hewitson G, McMahon J, Nair N, Moore P, Finger M, et al. A case of Japanese encephalitis with a fatal outcome in an Australian who traveled from Bali in 2019. Trop Med Infect Dis. 2020;5(3):133. doi:10.3390/tropicalmed5030133 .
   Google Scholar
• Australian Goverment - Department of Health. The Australian immunisation handbook - Imojev. 2018 [accessed 2021 Nov]. https://immunisationhandbook.health.gov.au/vaccines/imojev .
   Google Scholar
• Australian Goverment - Department of Health. The Australian immunisation handbook - JEspect. 2018 [accessed 2021 Nov]. https://immunisationhandbook.health.gov.au/vaccines/jespect .
   Google Scholar
• Australian Goverment - Department of Health. Japanese encephalitis. 2018 [accessed 2021 Nov]. https://immunisationhandbook.health.gov.au/vaccine-preventable-diseases/japanese-encephalitis.
   Google Scholar
• Nasveld PE, Ebringer A, Elmes N, Bennett S, Yoksan S, Aaskov J, McCarthy K, Kanesa-thasan N, Meric C, Reid M, et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccines. 2010;6(12):1038–46. doi:10.4161/hv.6.12.13057 .
   PubMed Web of Science ®Google Scholar
• Torresi J, McCarthy K, Feroldi E, Méric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Vaccine. 2010;28(50):7993–8000. doi:10.1016/j.vaccine.2010.09.035 .
   PubMed Web of Science ®Google Scholar
• Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Müller Z. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO®. Vaccine. 2011;29(47):8669–76. doi:10.1016/j.vaccine.2011.08.117 .
   PubMed Web of Science ®Google Scholar
• Dubischar-Kastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO®(IC51), in 6 months of follow-up. Vaccine. 2010;28(39):6463–69. doi:10.1016/j.vaccine.2010.07.040 .
   PubMed Web of Science ®Google Scholar
• Leeb A. SmartVax. 2009 [accessed 2021 Nov]. https://www.smartvax.com.au/ .
   Google Scholar
• Leeb A. SmartVax participating clinics. 2009 [accessed 2021 Nov]. https://www.smartvax.com.au/smartvax-participating-clinics/ .
   Google Scholar
• Leeb A, Regan AK, Peters IJ, Leeb C, Leeb G, Effler PV. Using automated text messages to monitor adverse events following immunisation in general practice. Med J Aust. 2014;200(7):416–18. doi:10.5694/mja13.11166 .
   PubMed Web of Science ®Google Scholar
• Chokephaibulkit K, Houillon G, Feroldi E, Bouckenooghe A. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children. Expert Rev Vaccines. 2016;15(2):153–66. doi:10.1586/14760584.2016.1123097 .
   PubMed Web of Science ®Google Scholar
• Jelinek T, Cromer MA, Cramer JP, Mills DJ, Lessans K, Gherardin AW, Barnett ED, Hagmann SHF, Askling HH, Kiermayr S, et al. Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: an uncontrolled, open-label phase 3 study. Travel Med Infect Dis. 2018;22:18–24. doi:10.1016/j.tmaid.2018.03.003 .
   PubMed Web of Science ®Google Scholar
• Chotpitayasunondh T, Pruekprasert P, Puthanakit T, Pancharoen C, Tangsathapornpong A, Oberdorfer P, Kosalaraksa P, Prommalikit O, Tangkittithaworn S, Kerdpanich P, et al. Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand. Vaccine. 2017;35(2):299–304. doi:10.1016/j.vaccine.2016.11.062 .
   PubMed Web of Science ®Google Scholar
• Ma H-Y, Lai -C-C, Chiu N-C, Lee P-I. Adverse events following immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV®) in Taiwan, 2017–18. Vaccine. 2020;38(33):5219–22. doi:10.1016/j.vaccine.2020.06.008 .
   PubMed Web of Science ®Google Scholar
• Kim HS, Oh Y, Korejwo J, Castells VB, Yang K. Post-marketing surveillance of adverse events following vaccination with the live-attenuated Japanese encephalitis chimeric virus vaccine (Imojev ®) in South Korea, 2015–2019. Infect Dis Ther. 2020;9(3):589–98. doi:10.1007/s40121-020-00305-6 .
   PubMed Web of Science ®Google Scholar
• Lammert SM, Rao SR, Jentes ES, Fairley JK, Erskine S, Walker AT, Hagmann SH, Sotir MJ, Ryan ET, LaRocque RC, et al. Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet. J Travel Med. 2016;24(1):taw075. doi:10.1093/jtm/taw075 .
   PubMed Web of Science ®Google Scholar
• Walker WL, Hills SL, Miller ER, Fischer M, Rabe IB. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012–2016. Vaccine. 2018;36(29):4369–74. doi:10.1016/j.vaccine.2018.04.038 .
   PubMed Web of Science ®Google Scholar
• Capeding MR, Alberto E, Feser J, Mooney J, Tang Y, Audet SA, Beeler JA, Ellison DW, Zhang L, Letson GW, et al. Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: a non-inferiority Phase 4 randomized clinical trial. Vaccine X. 2020;6:100074. doi:10.1016/j.jvacx.2020.100074 .
   PubMedGoogle Scholar
• Huang LM, Lin TY, Chiu CH, Chiu N-C, Chen P-Y, Yeh S-J, Boaz M, Hutagalung Y, Bouckenooghe A, Feroldi E, et al. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan. Vaccine. 2014;32(41):5363–69. doi:10.1016/j.vaccine.2014.02.085 .
   PubMed Web of Science ®Google Scholar
• Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, Paulke-Korinek M, Von Sonnenburg F, Spruth M, Tauber E, et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine. 2009;27(33):4483–89. doi:10.1016/j.vaccine.2009.05.034 .
   PubMed Web of Science ®Google Scholar
• Cramer JP, Jelinek T, Paulke-Korinek M, Reisinger EC, Dieckmann S, Alberer M, Bühler S, Bosse D, Meyer S, Fragapane E, et al. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series. J Travel Med. 2016;23(3). doi:10.1093/jtm/taw011 .
   PubMed Web of Science ®Google Scholar
• Jelinek T, Cramer JP, Dieckmann S, Hatz C, Paulke-Korinek M, Alberer M, Reisinger EC, Costantini M, Gniel D, Bosse D, et al. Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine. Travel Med Infect Dis. 2015;13(3):241–50. doi:10.1016/j.tmaid.2015.05.008 .
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet. 2007;370(9602):1847–53. doi:10.1016/S0140-6736(07)61780-2 .
   PubMed Web of Science ®Google Scholar
• Chen RT, Rastogi SC, Mullen JR, Hayes S, Cochi S, Donlon J, Wassilak S. The vaccine adverse event reporting system (VAERS). Vaccine. 1994;12(6):542–50. doi:10.1016/0264-410X(94)90315-8 .
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398–405. doi:10.1016/j.vaccine.2015.07.035 .
   PubMed Web of Science ®Google Scholar